Luncheon Symposium 14【Astellas】

16 Aug 2025 12:00 13:00

TICC - 1F 101C

Redefining the Trajectory of Prostate Cancer

This educational symposium puts the focus on changing the trajectory of the prostate cancer patient journey. It is structured around two core segments that explore optimized treatment approaches for non-metastatic (nmHSPC), and metastatic, hormone-sensitive prostate cancer (mHSPC). Featuring case-based learning, this practical symposium on these pertinent topics expounds current evidence to guide clinical decision-making in both settings.

In nmHSPC, the primary therapeutic goals are delaying disease progression and enhancing long-term outcomes. Central to this discussion is a case presentation of a patient with biochemical recurrence and no evidence of metastases. The faculty will compare currently-available treatment options.

Recently released EMBARK results will be discussed, highlighting the efficacy of enzalutamide-based approaches in this patient population. The engaging discussions will be centred around benefits and risks, such as those associated with androgen deprivation therapy (ADT) and enzalutamide. Further, the faculty will aim to provide insight into how therapy can be tailored (patient preference and tolerability), balancing clinical efficacy with a patient-centered approach.

This symposium will also address treatment intensification strategies in mHSPC, underscoring the importance of early combination therapy to extend progression-free survival (PFS) and overall survival (OS). The mHSPC discussions will be centered around new long-term data from pertinent studies.

Based on an mHSPC patient the discussions will focus around topics pertinent to day-to-day patient care, including the use of combination therapy, the implications of disease volume (low vs high), the presence of visceral vs bone metastases, and prior chemotherapy exposure.

By the end of the session, participants should have a clearer understanding of the latest treatment paradigms for HSPC patients, and an appreciation of real world considerations in the application of data to practice. Evidence-based clinical care, especially in the hormone sensitive space, can confer improved survival and treatment outcomes.

*Please note that hormone sensitive prostate cancer (HSPC) may be referred to as castration resistant prostate cancer (CSPC) in some countries

Time	Session

12:00 13:00	Redefining the Trajectory of Prostate Cancer Tai-Lung ChaTaiwan Moderator Novel Target for GU Cancer Metastasis and TherapeuticsCancer progression is shaped by both cell-intrinsic adaptations and complex extrinsic interactions within the tumor microenvironment (TME). Here, we identify a transmembrane protein, Meta1, as a shared therapeutic target that exhibits a Janus-like role: promoting malignant phenotypes in cancer cells while restraining tumor-supportive functions in non-cancerous stromal and immune cells. Meta1 is expressed in both compartments of the TME, orchestrating a dual program that supports metastasis and immune evasion. Mechanistically, we uncovered a malignancy-promoting factor (MPF) that acts as a functional ligand for Meta1, selectively enhancing pro-invasive signaling in cancer cells. We further identify Meta1 as an unconventional G protein–coupled receptor (GPCR) that plays as an accelerator in cancer cells of the TME. Meta1 interacts with Rho-GDI and Gαq to activate RhoA-mediated cytoskeletal remodeling and amoeboid migration, facilitating metastatic dissemination. We further identify MPF binding to Meta1 initiates Gβγ signaling, elevating intracellular cAMP and activating Rap1, thereby amplifying cell motility and metastatic potential. Leveraging the Meta1–MPF interaction, we designed MPF-derived peptides that specifically bind Meta1 and serve as the basis for a novel peptide-based PROTAC, which efficiently induces degradation of Meta1 and abrogates its pro-metastatic functions. Our study unveils Meta1 as an atypical GPCR with canonical signaling capacity and topological divergence, representing a shared and targetable vulnerability that bridges cancer cell-intrinsic adaptation with extrinsic TME communication. These findings establish the Meta1–MPF axis as a compelling therapeutic target for suppressing metastasis and reprogramming the TME. Chun-Te WuTaiwan Moderator 健保各領域審查共識及討論－泌尿腫瘤 Henry WooAustralia Speaker Bertrand TombalBelgium Speaker Impact of Relugolix versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study (European Urology, 2023)

Time

Session

12:00

13:00

Redefining the Trajectory of Prostate Cancer

Tai-Lung ChaTaiwan Moderator Novel Target for GU Cancer Metastasis and TherapeuticsCancer progression is shaped by both cell-intrinsic adaptations and complex extrinsic interactions within the tumor microenvironment (TME). Here, we identify a transmembrane protein, Meta1, as a shared therapeutic target that exhibits a Janus-like role: promoting malignant phenotypes in cancer cells while restraining tumor-supportive functions in non-cancerous stromal and immune cells. Meta1 is expressed in both compartments of the TME, orchestrating a dual program that supports metastasis and immune evasion. Mechanistically, we uncovered a malignancy-promoting factor (MPF) that acts as a functional ligand for Meta1, selectively enhancing pro-invasive signaling in cancer cells. We further identify Meta1 as an unconventional G protein–coupled receptor (GPCR) that plays as an accelerator in cancer cells of the TME. Meta1 interacts with Rho-GDI and Gαq to activate RhoA-mediated cytoskeletal remodeling and amoeboid migration, facilitating metastatic dissemination. We further identify MPF binding to Meta1 initiates Gβγ signaling, elevating intracellular cAMP and activating Rap1, thereby amplifying cell motility and metastatic potential. Leveraging the Meta1–MPF interaction, we designed MPF-derived peptides that specifically bind Meta1 and serve as the basis for a novel peptide-based PROTAC, which efficiently induces degradation of Meta1 and abrogates its pro-metastatic functions. Our study unveils Meta1 as an atypical GPCR with canonical signaling capacity and topological divergence, representing a shared and targetable vulnerability that bridges cancer cell-intrinsic adaptation with extrinsic TME communication. These findings establish the Meta1–MPF axis as a compelling therapeutic target for suppressing metastasis and reprogramming the TME.

Chun-Te WuTaiwan Moderator 健保各領域審查共識及討論－泌尿腫瘤

Henry WooAustralia Speaker

Bertrand TombalBelgium Speaker Impact of Relugolix versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study (European Urology, 2023)